五藤冲剂联合甲氨蝶呤治疗类风湿关节炎的临床研究

目的:观察自拟五藤冲剂联合甲氨蝶呤治疗类风湿关节炎的临床疗效及安全性。方法:将102例类风湿关节炎患者随机分为治疗组52例，观察组50例，观察组口服甲氨蝶呤片，治疗组在观察组基础上加口服自拟五藤冲剂，疗程12周，观察治疗前后患者的症状、体征及实验室相关指标的变化。结果 治疗组总有效率96.00%，观察组总有效率81.63%，二者比较有统计学差异（P＜0.05）；治疗后两组在压痛关节数、压痛指数、肿胀指数、晨僵时间、握力、HAQ评分方面均有显著性差异（P＜0.01），在肿胀关节数、DAS28评分、CRP方面有统计学差异（P＜0.05），在VAS评分、ESR方面无统计学差异（P＞0.05）。结论 自拟五藤冲剂联合甲氨蝶呤治疗类风湿关节炎可显著改善患者症状、体征及炎性指标，显著优于单用甲氨蝶呤。

Clinical Curative Effects Observation of Wuteng Chongji and Methotrexate in the Treatment of Rheumatoid Arthritis

OBJECTIVE To observe the clinical curative effects and safety of Wutengchongji and methotrexate in the treatment of rheumatoid arthritis. METHODS 102 cases of rheumatoid arthritis patients were randomly divided into for 52 cases of treatment group, 50 cases in the observation group, observation group oral methotrexate tablets, treatment group in the observation group on the basis of the oral Wutengchongji, and the course of treatment was 12 weeks observed before and after treatment in patients with symptoms, signs and laboratory indicators of change. RESULTS in the treatment group, the total effective rate was 96.00%. In the observation group, the total efficiency of 81.63%, compare the two groups had significant difference (P < 0.05); after treatment in the two groups in the tender joint number, tenderness index, swelling index, time of morning stiffness, grip strength, HAQ score have significant difference (P < 0.01), swollen joint count, DAS28, CRP have statistical difference (P < 0.05), the VAS score, ESR no statistical difference (P > 0.05). CONCLUSION Wutengchongji and methotrexate in the treatment of rheumatoid arthritis can significantly improve symptoms, signs and inflammatory index. They are better than single use of methotrexate tablets.